Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Epacadostat vs EXTREME in First-line SCCHN
NCT03342352Phase 3Withdrawn
- Sponsor
- Incyte
- Start
- Dec 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of epacadostat in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Incyte. Planned start Dec 2017; status: withdrawn.
02
Drugs
epacadostat
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03342352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342352.